In a market dominated by pills and pumps, Comphya is betting on electricity. Their neurostimulator promises a physiological fix for erectile dysfunction, but their digital footprint suggests they're either playing stealth mode or struggling to launch.

"Zero web traffic for a medical device with $1.3M in revenue isn't a failure—it's a sign of a B2B or clinical sales model that bypasses consumer marketing entirely."

The keyword strategy reveals a fragmented market. Terms like 'electrical implant stimulator for erectile dysfunction' (190 monthly volume) and 'new erectile dysfunction trainer' (320 monthly volume) show consumers are actively seeking alternatives to traditional treatments. Comphya's domain ranks #5.3M globally, meaning they're invisible to organic search. For a medical device, this is both a liability and a strategic choice. Liability: no inbound leads. Strategic choice: they likely rely on physician referrals and clinical trials, not Google Ads.

• Revenue per employee: $144k (efficient for hardware)
• Search interest in 'caverstim' exists but isn't monetized
• Tech stack suggests legacy approach, not innovation-first
• Zero traffic implies clinical/B2B sales model